



Aeromedical Consideration in Ophthalmology

A Case-based Approach

WG.CDR.TAECHIT MIRASENA, M.D.
CONSULTANT IN AVIATION MEDICINE AND OPHTHALMOLOGY

-
- Doctor of Medicine, Chulalongkorn University, 2008
 - Certificate of Aviation Medicine, RTAF Institute of Aviation Medicine, 2009
 - Certificate of Human Centrifuge (8G Profile), RSAF Aeromedical Centre, Singapore, 2011
 - Flight Surgeon Training Program, Flugmedizinisches Institut der Luftwaffe, Germany, 2011-2013
 - Diplomate Thai Board of Preventive Medicine (Aviation Medicine), 2014
 - Residency Training in Ophthalmology, Chulalongkorn University, 2015-2018
 - Diplomate Thai Board of Ophthalmology, 2018
 - Certificate of Occupational Medicine, Nopparat Rachathani Hospital, 2021

Wg.Cdr. Taechit Mirasena M.D.

Certified Aviation Medical Examiner, CAAT

AeMC - RTAF Institute of Aviation Medicine, Samitivej Srinakarin Hospital



I have no conflicts of interest to disclose
Consent was given for educational purposes only

CASE 1 : Visual Acuity is not equal to Vision


General Information


- ❖ Thai male captain of airline, age 52 years
- ❖ Fleet Boeing-777, Total Flight Hours 18,000 Hrs
- ❖ ATPL, Class 1 Medical Certificate
- ❖ Apply for renewal of medical certificate at AeMC Samitivej Srinakarin Hospital
- ❖ Normal general physical examination

Ophthalmic History&Examination

- ❖ Hx. Cataract, S / P Phacoemulsification+IOL OD 15 Dec 2020, OS 22 Dec 2020
- ❖ No intra-op or post-op complications from cataract surgery
- ❖ No history of other eye diseases, no family history of any eye diseases
- ❖ Distant UCVA OD 20 / 20, OS 20 / 20, OU 20 / 20
- ❖ Near UCVA OD 20 / 20, OS 20 / 20, OU 20 / 20
- ❖ Color test - Ishihara 38 Plates edition: PASS
- ❖ AS: Good wound, Clear Cornea, A / C formed, IOL in place OU

OD







Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 1/22
 False POS Errors: 4 %
 False NEG Errors: 3 %
 Test Duration: 07:51

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 5.1 mm
 Visual Acuity:
 RX: +1.50 DS DC X

OS

Fovea: 38 dB





1	-1	5	3
1	-1	-1	1
2	0	1	-3
2	1	1	-6
2	3	-5	-34
-2	1	-6	-19
0	-2	-4	-2
-3	-1	-3	-7
-2	0	0	-1
-1	1	0	-1

0	-2	5	3
0	-1	-2	0
2	-1	0	-4
1	0	0	-6
1	2	-6	-35
-2	1	-6	-19
0	-2	-5	-2
-4	-2	-3	-8
-2	-1	-1	-1
-1	1	-1	-2

GHT
 Outside Normal Limits
 VFI 63%
 MD -7.44 dB P < 0.5%
 PSD 13.32 dB P < 0.5%

Total Deviation

Pattern Deviation



∴ < 5%
 ∴ < 2%
 ∴ < 1%
 ■ < 0.5%



Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 1/25
 False POS Errors: 2 %
 False NEG Errors: 6 %
 Test Duration: 09:34

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 5.3 mm
 Visual Acuity:
 RX: +1.50 DS DC X

OD

Fovea: 37 dB





2	3	0	2
-2	1	0	-7
-3	-1	-1	-3
0	-1	0	-4
-2	-3	-12	-34
0	-6	-34	-35
-4	-4	-14	-19
-1	-4	-6	-9
-2	0	-2	-3
-2	1	-3	1

3	4	0	2
-2	2	1	-6
-2	0	0	-2
0	0	1	-3
-1	-3	-11	-34
0	-6	-33	-34
-3	-3	-13	-18
0	-3	-5	-8
-1	1	-1	-2
-1	2	-2	2

GHT
 Outside Normal Limits
 VFI 56%
 MD -10.22 dB P < 0.5%
 PSD 14.01 dB P < 0.5%

Total Deviation

Pattern Deviation



∴ < 5%
 ∴ < 2%
 ∴ < 1%
 ■ < 0.5%


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 4/15 xx
 False POS Errors: 2 %
 False NEG Errors: 2 %
 Test Duration: 06:19

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 6.1 mm
 Visual Acuity:
 RX: +2.00 DS DC X

OS

Fovea: 39 dB



1	1	4	4
1	1	-3	0
-1	-3	-8	-4
-2	-9	-8	-17
-4	-2	-8	-31
-6	-5	-1	-12
-2	-2	-2	-6
0	1	-1	-4

Total Deviation



0	0	3	3
0	0	-4	-1
-2	-5	-9	-5
-3	-10	-9	-18
-5	-3	-9	-32
-7	-6	-2	-13
-3	-3	-3	-7
-1	0	-2	-5

Pattern Deviation

*** Low Test Reliability ***

GHT
 Outside Normal Limits

VFI 79%
 MD -5.14 dB P < 0.5%
 PSD 7.15 dB P < 0.5%



∴ < 5%
 ∴ < 2%
 ∴ < 1%
 ∴ < 0.5%


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/18 ✓
 False POS Errors: 8 % ✓
 False NEG Errors: 0 % ✓
 Test Duration: 07:55

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 6.7 mm
 Visual Acuity:
 RX: +2.25 DS DC X

OD

Fovea: 39 dB



2	1	2	-1
2	-1	-1	0
0	-1	-5	-3
0	-1	-5	-24
-1	-1	-24	-35
-3	-4	-32	-26
-4	-7	-7	-5
-4	2	-2	-3



Total Deviation

2	1	2	-1
2	-1	-1	0
0	-1	-5	-3
0	-1	-5	-23
-1	-1	-24	-35
-3	-4	-32	-26
-4	-7	-6	-5
-4	2	-2	-2

Pattern Deviation

GHT
 Outside Normal Limits

VFI 61%
 MD -9.90 dB P < 0.5%
 PSD 12.91 dB P < 0.5%





∴ < 5%
 ∴ < 2%
 ∴ < 1%
 ∴ < 0.5%

OD

IR 30° ART [HS]

14 / 25





Center: 254 μm
Central Min: 217 μm
Central Max: 301 μm

Circle Diameters:
1, 3, 6 mm ETDRS

OS

IR 30° ART [HS]


13 / 25




Center: 220 μm
Central Min: 211 μm
Central Max: 271 μm

Circle Diameters:
1, 3, 6 mm ETDRS

OCT 20° (6.0 mm) ART (7) Q: 31 [HS]




OCT 20° (5.9 mm) ART (10) Q: 30 [HS]





OCT OD

OD(R)


Image Quality 96 Analysis mode Fine (2 0 7)
Capture Date 27/05/2021



Red-free




OCTA OD





OCT OS

OS(L)


Image Quality 99 Analysis mode Fine (2.0 7)
Capture Date 27/05/2021




Red-free



OCTA OS



Fundus Autofluorescence



Dx. Stargardt's Disease Stage I
with Foveal sparing

Epidemiology&Genetic


- ❖ STGD is the most commonly inherited childhood and adulthood maculopathy.
- ❖ It has a prevalence of 1 in 10,000.
- ❖ Stargardt Disease (STGD) is most commonly caused by mutations in the **ABCA4 gene** located on chromosome 1 and is inherited in an **autosomal recessive** manner.
- ❖ Mutations in this gene result in accumulation of N-retinylidene-N-retinyl-ethanolamine (A2E), a component of lipofuscin that is known to be toxic to RPE and photoreceptors.

Clinical Findings

- ❖ Patients with STGD typically present in childhood or early adolescence, but some may present in later adulthood.
- ❖ Initial symptoms include bilateral central visual loss characterized by blurred vision, central scotomas, and / or dyschromatopsia.
- ❖ The visual acuity (VA) at presentation **varies from 20/20 to 20/400**, with earlier age of onset having a worse visual prognosis.


Clinical Findings

- ❖ In up to two-thirds of patients, the macula is classically described as “beaten bronze metal” appearance with yellowish, “fish-tail” or pisciform lesions in up to two-thirds of patients
- ❖ Interestingly, classic flecks are absent in approximately 30% of patients with childhood onset disease.



Clinical Findings


- ❖ The maculopathy then progresses slowly to a characteristic atrophic macular degeneration classically resulting in a “bull’s eye” pattern.



Investigation

Spectral-Domain Optical Coherence Tomography (SD-OCT)


- ❖ The hallmark of STGD is outer retinal foveal atrophy and loss of the inner ellipsoid band
- ❖ The earliest OCT finding in children is thickening of the external limiting membrane prior to outer retinal atrophy.



Investigation

Fundus Autofluorescence (FAF)

- ❖ It allows early identification of RPE pathology prior to clinical manifestations.
- ❖ There is initially a hyperautofluorescent signal, which is likely due to lipofuscin accumulation in the RPE, progressing over the disease course to hypoautofluorescence, which is thought to result from RPE death.



Progression

- ❖ VA in STGD is highly correlated with both the diagnostic stage and the patient age at the initial diagnosis.
- ❖ In general, stage 1 STGD patients have VA better than 20 / 200, while those in stages 2, 3, and 4 have a VA of 20 / 200 or worse.
- ❖ In particular, patients initially diagnosed before the age of 20 years have an average VA decline from 20 / 40 to 20 / 200 over a follow-up period of 7 years.
- ❖ In contrast, VA decline is less progressive in those presenting between ages 21-40 and 41-60 years, whose VA declines over approximately 22 and 29 years, respectively.
- ❖ Not surprisingly, patients with foveal sparing have a VA of 20 / 40 or better.

Treatment

- ❖ Currently, **there is still no proven treatment** to halt or reverse STGD-related maculopathy.
- ❖ Early diagnosis is essential for low vision interventions, vocational and educational modifications, and family planning.
- ❖ Several promising treatment options are being investigated in humans. Essentially, the treatment options targeting STGD maculopathy are gene replacement therapies, stem cells therapies, or pharmacologic therapies.

Aeromedical Consideration

- ❖ **UNFIT for Class 1 Medical Certificate**
 - ❖ Due to Central Scotoma in Visual Field of Both Eyes
- ❖ Deferred to Board of Aeromedical Specialist for Special Issuance
 - ❖ Condition: Medical Flight Test

Medical Flight Test

Medical Assessor

- ❖ AM.Manop Chitcharas, M.D.
- ❖ Wg.Cdr. Taechit Mirasena, M.D.



Flight Assessor

- ❖ Captain Noppon Wilairat, M.D.
- ❖ Chakatat Chiemchan, M.D.

Condition for testing

- ❖ Manual approach and landing in very low visibility&contrast
- ❖ Manual approach and landing in night







Aeromedical Consideration

- ❖ **UNFIT for Class 1 Medical Certificate**
 - ❖ Due to Central Scotoma in Visual Field of Both Eyes
- ❖ Medical Flight Test: **PASSED**
- ❖ **Special Issuance with Limitations**
 - ❖ OML (Valid only as or with qualified co-pilot)
 - ❖ RXO (Special ophthalmological examination) - CTVE, OCT, FAF q1yr

Case 2: Be color safe in Aviation - How much?

6.2.4 Colour perception requirements

6.2.4.1 Contracting States shall use such methods of examination as will guarantee reliable testing of colour perception.

6.2.4.2 The applicant shall be required to demonstrate the ability to perceive readily those colours the perception of which is necessary for the safe performance of duties.

6.2.4.3 The applicant shall be tested for the ability to correctly identify a series of pseudoisochromatic plates in daylight or in artificial light of the same colour temperature such as that provided by CIE standard illuminants C or D₆₅ as specified by the International Commission on Illumination (CIE).

6.2.4.4 An applicant obtaining a satisfactory result as prescribed by the Licensing Authority shall be assessed as fit. An applicant failing to obtain a satisfactory result in such a test shall be assessed as unfit unless able to readily distinguish the colours used in air navigation and correctly identify aviation coloured lights. Applicants who fail to meet these criteria shall be assessed as unfit except for Class 2 assessment with the following restriction: valid daytime only.

Note.— Guidance on suitable methods of assessing colour vision is contained in the Manual of Civil Aviation Medicine (Doc 8984).

History

Male Pilot age 73, PPL

- Initial examination on 26 March 1990, age 39, at IAM RTAF
- Record in initial examination Report
 - Color blindness
 - Lantern test pass, could differentiate emergency light
 - Color defect - SAFE
 - Fit for class 2
 - Limitation - corrective lens for distant and near vision are required

Lantern test

First color vision test ever

- In the second half of the 1800's, several spectacular train wrecks occurred
- This led to the discovery that some of the people responsible for these trains were color blind
- In 1899, ophthalmologist, Dr. Charles H. Williams of Boston constructed a lantern to test the color vision of railway men




Lantern test

Research study

- In 1943 the US Navy tested this lantern for suitability of detecting color deficiencies and found it
- Difficult to interpret. Normal observers made similar responses
- Possible correlated poorly with present standard tests
- Awkward and confusing to operate
- It is entirely unsuited for Navy use

Farnsworth D. *Examination of the Williams lantern as a test for color vision.*
US Naval Medical research laboratory report no.31;1943


AD622184

MEDICAL RESEARCH LABORATORY											
											
U.S. Naval Submarine Base New London											
Vol II, No. 18	REPORT No. 31	1943									
Summary and Conclusions, Extract from											
EXAMINATION OF THE WILLIAMS LANTERN AS A TEST FOR COLOR VISION											
Color Vision Report No. 6		<table border="1"> <tr> <td colspan="2">FOR FEDERAL ARCHIVE AND TECHNICAL INFORMATION</td> </tr> <tr> <td>Hardcopy</td> <td>Microfilm</td> </tr> <tr> <td>\$ 1.00</td> <td>\$ 0.50</td> </tr> <tr> <td colspan="2">5 pp. a</td> </tr> </table>		FOR FEDERAL ARCHIVE AND TECHNICAL INFORMATION		Hardcopy	Microfilm	\$ 1.00	\$ 0.50	5 pp. a	
FOR FEDERAL ARCHIVE AND TECHNICAL INFORMATION											
Hardcopy	Microfilm										
\$ 1.00	\$ 0.50										
5 pp. a											
Prepared by Lt. Leon Farnsworth, II-V(S) USNR assisted by J. D. Reed, PhM, 1c, USNR		ARCHIVE COPY PROCESSING COPY									
Approved: Comdr. C.W. Shilling, (MC) USN Medical Research Laboratory U.S.N. Submarine Base New London, Connecticut											
22 November 1943											

Best Available Copy

FALANT

Farnsworth Lantern Test



Farnsworth Lantern (FALANT)

- After its adoption by the United States Navy in 1954 as the standard color vision test for seamen, it has additionally been used to screen pilots.
- It was designed to qualify 20% of color deficiencies but recent studies have shown it to pass much more severe defects
- The US Air Force discontinued use of the FALANT in 1993 due to its frequent failure to identify cases of color deficiency considerably more serious than the test was intended to let pass

Lantern testing with a Spectrolux, Beynes or Holmes-Wright lantern. This test is considered passed if the applicant passes without error a test with accepted lanterns.


EASA AMC to Part-MED 2019
AMC1 MED.B.075 Colour vision (Class 1)



Holmes Wright





Beynes



Spectrolux

The applicants who failed Ishihara test shall be evaluated with secondary tests approved by Aeromedical Department, CAAT (Anomaloscopy or **Color Lanterns**) to ensure that they have adequate color perception which is necessary for the safe performance of duties.

CAAT Standards for Medical Certificate 2019 (Old Version)
Appendix 2 Number 2.14 - Color vision standards



Application in real life!

Is it safe enough???

The cockpit of the past

Only simple color indicator



...and Nowadays

Multispectral color display



Even in the private aircraft

Shark Aero - Diamond DA42



Airport Runway Lighting

Multicolor light signal



Airport Runway Lighting

The most important - PAPI



The crash of FedEx flight 1448 (a Boeing 727) in Tallahassee, Florida in July 2002



CAD Test


Color Assessment and Diagnosis Test



Scoring CAD


CIE 1931 Diagram

- Chromatic discrimination thresholds have been measured in 250 normal trichromats and 200 color deficiency observers
- The median threshold value is the **Standard Normal (SN)** observer
- A subject's thresholds can be expressed in SN units and this makes it possible to assess the severity of color vision loss




Interpretation of CAD

Severe deficiency




Deuteranopia



Protanopia

CAD Safety Threshold in Aviation

Critical color perception tasks (PAPI)



Approximate 35% of color deficient pilot applicants will pass the CAD test

Colour Assessment and Diagnosis (CAD) test. This test is considered passed if the threshold is less than 6 standard normal (SN) units for deutan deficiency, or less than 12 SN units for protan deficiency.

EASA AMC to Part-MED 2019
AMC1 MED.B.075 Colour vision (Class 1)

วันเกิด: 07 เม.ย. 2493

อายุ: 72-5-12 ปี

ชุดตรวจ: 20105 A'S TEST 38 PLATES

สิทธิ์ : เงินสด

เหล่า : นักบิน

สังกัด : ส่วนบุคคล (L/C Class II)

วันที่ตรวจ: 19/09/2565-08:26:11 Pers.

	Normal	Person with RG Deficiencies	Person with total color blindness and weakness
1	12	12 ✓	
2	8	-	
3	6	6 ✓	
4	29	13	
5	57	-	
6	5	2	
7	3	3 ✓	
8	15	17	
9	74	21	
10	2	-	
11	6	-	
12	97	-	
13	45	-	
14	5	-	
15	7	-	
16	16	-	
17	73	23	
18	-	37	
19	-	8	
20	-	45	
21	-	23	
22	26	-	
23	42	30	
24	35	-	
25	96	-	


Score Sheet Template for 15 Disc Color Vision Test

Name: 1 DOB: 7/4/2493 Test Date: 21/3/65


Mode: Binocular ✓ or OD OS Tester: Phatchara Bamrungrad.

Copy this template onto your medical history or plain paper

(Binocular Test 1
or OD Test 1)



(Binocular Re-Test
or OS Test 1)



astigmatism plan in
OAO screening
+ 20/20/1000
[Signature]

*but Lentern test pass

Richmond Products
100 Silver Ave. SE Albuquerque NM 87108

Richmond Part Number 4428

Summary

Male Pilot age 73, PPL

- Last examination 30 Sep 2022 (Before new regulations was released)
- Record in eye examination report
 - Color deficiency - Failed Ishihara and Farnsworth D-15
 - **Lantern test passed**
 - Fit for class 2
 - Limitation - corrective lens for distant and near vision are required

Those failing the Ishihara test should be examined by Colour Assessment and Diagnosis (CAD) test. This test is considered passed if the threshold is less than 6 standard normal (SN) units for deutan deficiency, or less than 12 SN units for protan deficiency.

Applicants who fail to meet these criteria shall be assessed as unfit except for Class 2 assessment with the following restriction: valid daytime only.

CAAT Standards for Medical Certificate 2022 (Current Version)

Appendix 5 Number 5.15 - Color vision standards

Lastest renewal examination: 29 Mar 2023

Telephone
Email
Comments
Date of test

Results

Environment Aviation (commercial)

Max. RG norm 2.200926018 (SNU)


Max. YB norm 2.371656275 (SNU)

Diagnosis
deutan deficiency
deficient YB colour vision
acquired deficiency likely

Certification fail

r-g threshold 25.16 (SNU)

y-b threshold 12.15543556 (SNU)



CAD Test - Deutan deficiency 25.16 SNU - Failed

Add Limitation: Valid Daytime Only

A gap between the regulations

Any Questions?



Thank you for your attention!